ORIC Stock — Oric Pharmaceuticals Inc.: Cash, EV, Pipeline

What they do

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by O vercoming R esistance I n C ancer . Profound advancements in oncology drug development have expanded the treatment options available to patients, yet therapeutic resistance and relapse continue to limit the efficacy and duration of clinical benefit of such treatments.

Source: 10-K FY2025 via SEC EDGAR

Share price

$8.82

Market cap

$914.2M

Cash

$387.6M

Enterprise value

$526.6M

Balance sheet

Cash	$387.6M
Debt	$0.0M
Net cash	$387.6M
Enterprise value	$526.6M
Basic shares	103.7M shares
Fully diluted shares	126.4M shares
Fully diluted market cap	$1,114.8M
Cash per share	$3.74
Quarterly burn	$31.6M
Cash runway	12.3 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

103.7M

Pre-funded warrants

4.5M

Options

17.2M

RSUs

1.1M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

126.4M

Cap table as of 2026-06-30.

Price history

Loading ORIC daily closes…

Loading price history…

Next catalyst

ORIC-114 · Now - Nov 24, 2026 Now · Phase 1/2 · Solid Tumors

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 24, 2026 Now	ORIC-114	Phase 1/2	Solid Tumors	October 2026 2H 2026 Est. Nov 7, 2026 · half midpoint
Jan 12 - Feb 23 in 9 wks	ORIC-114 Dose 1	Phase 1	Solid Tumors; EGFR Exon 20 Insertion Mutations; NSCLC	October 2026 2H 2026 Est. Nov 7, 2026 · half midpoint
Jul 13 - Aug 24 in 8 mo	ORIC-944	Phase 1	Metastatic Prostate Cancer	—
Apr 12 - May 24 in 17 mo	Rinzimetostat	Phase 3	Metastatic Castration Resistant Prostate Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

rinzimetostat

Phase 3 · Active Modality: small molecule (allosteric inhibitor)

Aliases ORIC-944

Target PRC2 (EED subunit)

Partnerships Mirati Therapeutics (licensed rights); Bayer (darolutamide supply for Himalayas-1, July 2026); Johnson & Johnson (apalutamide supply for Phase 1b combo)

Indications

metastatic castration-resistant prostate cancer (mCRPC) (Phase 3)

Catalysts

— July 2026

Status note Allosteric inhibitor of PRC2 via the EED subunit, designed for superior properties vs EZH2 inhibitors. RP3D selected March 2026: 400 mg QD rinzimetostat + darolutamide in mCRPC patients previously treated with abiraterone. Himalayas-1 Phase 3 initiated July 2026.

enozertinib

Phase 1 · Active Modality: small molecule (brain-penetrant, orally bioavailable, irreversible inhibitor)

Aliases ORIC-114

Target EGFR

Partnerships Voronoi Inc. (licensed development and commercialization rights)

Indications

non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion and PACC mutations (Phase 1)

Status note Being evaluated in Phase 1b trials in EGFR exon 20 insertion and P-loop/alpha C-helix compressing (PACC) mutated NSCLC, allowing enrollment of patients with treated or untreated asymptomatic CNS metastases.

Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Rinzimetostat
Lead indication	Metastatic Castration Resistant Prostate Cancer
Lead phase	Phase 3
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07723248	Phase 3	Recruiting	Sponsor	ORIC Pharmaceuticals	—	Metastatic Castration Resistant Prostate Cancer	—
NCT05315700	Phase 1/2	Recruiting	Sponsor	ORIC Pharmaceuticals	—	Solid Tumors	October 2026 2H 2026 Est. Nov 7, 2026 · half midpoint
NCT06816992	Phase 1	Recruiting	Sponsor	ORIC Pharmaceuticals	JNJ	Solid Tumors; EGFR Exon 20 Insertion Mutations; NSCLC	October 2026 2H 2026 Est. Nov 7, 2026 · half midpoint
NCT05413421	Phase 1	Recruiting	Sponsor	ORIC Pharmaceuticals	—	Metastatic Prostate Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for ORIC Pharmaceuticals on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
EcoR1 Capital	6,728,116	no change	3.61%	2026-08-14
OrbiMed Advisors	2,015,000	-678,929	0.41%	2026-08-14
Vivo Capital	1,848,786	no change	1.83%	2026-08-14
Braidwell LP	1,214,540	+86,500	0.49%	2026-08-14
Sphera Biotech	752,983	+215,355	1.17%	2026-08-14
Boxer Capital	350,000	+173,500	0.29%	2026-08-14
Logos Global Management	0	-950,000	0.00%	2026-08-14
DAFNA Capital	0	-98,724	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ORIC — Oric Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ORIC — Oric Pharmaceuticals Inc.